For full details of each session, please view the event guide.

8:00 am

Registration & Welcome Coffee

8:45 am Chair’s Opening Remarks

Humanised Mouse Models

9:00 am Targeting of Tumor-Specific HLA Ligands with Bispecific T Cell-Engaging Receptor (TCER™) Molecules

  • Sebastian Bunk Senior Director Immunology, Head of TCR Engineering & Bispecifics, Immatics

Synopsis

  • XPRESIDENT® to exploit the repertoire of tumor-associated antigens
  • Introduction into TCER™, Immatics’ TCR bispecific molecules
  • TCER™ in vivo data

9:30 am Assessment of Different Humanised Mouse Models for the Evaluation of Cancer Immunotherapies

  • Loreley Calvet Laboratory Head Drug Discovery & Preclinical Development , Sanofi-Oncology

Synopsis

  • Comparison of humanisation of immune system with huCD34+ HSC in different strains of immune-deficient mice (NSG, NSG SGM3, NOG & NOG-EXL)
  • Evaluation of humanised PBMC mouse models
  • Insight into the response of immunotherapies in different humanised mouse models with tumours (PDX and CDX)

10:00 am Advancing immuno-oncology therapies: what are the next generation syngeneic models?

Synopsis

  • ICI Treatment & Dissecting the Mechanism Of Action (MOA)
  • Immune Cells Impacting Syngeneic Tumorgenicity
  • Tool GEMMs for MoA

10:30 am

Speed Networking & Morning Break

Syngeneic & PDX Models

11:30 am The Clinical IAP Antagonist ASTX660 Drives Anti-Tumor Immunity in T Cell Lymphoma

  • Nicola Ferrari Research Associate- Translational R&D, Astex Pharmaceuticals

Synopsis

  • ASTX660 is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP, which has demonstrated preliminary evidence of single agent clinical activity in T cell lymphoma (TCL) patients
  • To investigate the mechanism of action behind the single agent activity seen in the clinic we have used a comprehensive translational approach via the integration of in vitro coculture systems and in vivo preclinical models with human patient data from our clinical trial
  • We describe a novel role for ASTX660 as an immunomodulatory molecule, capable acting on both the innate and adaptive immune system, which could be exploited to remodel the tumor immune microenvironment

12:00 pm Zebrafish Tumor Xenograft models: A new translational in-vivo tool for oncology drug discovery

Synopsis

  • Zebrafish as in-vivo model system for oncology
  • Zebrafish models for analysis of human tumor- and tumor-infiltrating cell interactions
  • Zebrafish as complementary models to mouse PDX studies

12:15 pm Considerations for the correct implementation of PDX models in Immuno-Oncology

Synopsis

  • What are Patient Derived Xenograft (PDX) models?
  • Traditional versus humanised PDX models
  • Generation of PDX models for Immuno-Oncology?
  • Applications of PDX models in Immuno-Oncology

12:45 pm SubQperior: A Superior Syngeneic Model System to Subcutaneous Tumour Models

  • Holger Weber Head of In Vivo Pharmacology, Reaction Biology Europe GmbH

Synopsis

  • Introducing the next generation of tumour models for immuno-oncology efficacy studies overcoming common problems experienced with subcutaneous tumour implantation

1:00 pm

Networking Lunch

2:00 pm Panel Discussion: Limitations of Humanised & PDX Models

Synopsis

  • How can we push these borders to include more supporting immune cells, dendritic cells, NK-cells?
  • Increasing longevity; CD34 humanised hyper immune-deficient mice can increase available study lengths but also increase the cost. Is there a middle ground?
  • Gaining data on persistence of cellular therapies without requiring additional mice

2:45 pm Immune Checkpoints; Humanised Preclinical Models for Biologics’ Efficacy & MoA

  • Kader Thiam Vice President of Transgenic Technologies, genOway

Synopsis

  • Exploring how model design impacts the physiological relevance and the predictability of preclinical outcomes

Afternoon Tea Break

Next Generation Preclinical Models for IO

3:30 pm Targeting Kras: Pros and Cons of In Vitro Tools Versus Mouse Models

  • Chiara Ambrogio Assistant Professor MBC (Molecular Biotechnology Centre), University of Turin

Synopsis

  • Can genetic models discriminate between tumour initiating and tumour maintaining effects of KRAS?
  • Can we improve the identification of biomarkers for better treatment options?
  • Can genetic models be used to predict the toxicity of new KRAS-specific drugs?

3:45 pm The Role of Biomarkers in the Transition from Preclinical Models to Clinical Trials in Immuno-Oncology

Synopsis

 

  • Overview of different biomarkers and their functions
  • Preclinical immuno-oncology models and biomarkers
  • Brief discussion of biomarkers in immuno-oncology clinical trials

4:00 pm Round Table Discussion: Biomarkers in Immuno-oncology – From Preclinical Approaches Through Clinical Trials

  • Maryland Franklin Executive Director Scientific Development, Covance
  • Suso Platero Head of Biomarker Solution Center & Global Leader - Precision Medicine , Covance

Synopsis

  • Discuss various biomarker platforms/technologies for preclinical immuno-oncology studies
  • Discuss how the use of biomarkers in preclinical immuno-oncology studies can provide guidance for clinical studies
  • Discuss biomarker approaches for immuno-oncology clinical trials

5:00 pm Drinks Reception & Round Table: What preclinical models provide a platform to assess immunotherapy toxicology?

  • Ludovic Bourré Senior Director Scientific Engagement, Crown Bioscience
  • Georgina Cornish Associate Principle Scientist, Cell Therapy Safety Oncology Safety Science & Discovery , AstraZeneca, R&D, Clinical Pharmacology & Safety Sciences

Synopsis

Drinks Reception and Working Group Hosted by Crown Bio

• How to use mouse models to assess irAE?
• Looking at cytokine release in PBMC/CD34+ models – what does that tell us?